**Supplementary Methods Table 1.**

**Supplementary Methods Table 1.** *In vivo* drug treatments of the monotherapy study in BT183 xenografts are listed with their respective number of treated animals, dosing, administration, treatment schedule and dissolver of the compound. *i.v. = intravenous; p.o.= per os (oral gavage); i.p. = intraperitoneal; HPCD = 10% 2-hydroxypropyl-β-cyclodextrin/1% sodium bicarbonate ; PVP = polyvinylpyrrolidone K 30; NMP = 1-methyl-2-pyrrolidinone;*

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| Treatment | # of animals | Dosis | Administration | Treatment schedule | Dissolver/Vehicle |
| Vehicle | 18*(2-3 animals per dissolvent)* | *According to the respective drug treatment* | *According to the respective drug treatment* | *According to the respective drug treatment* | SalineNaCl/Saline5% NMP/15% PVP10% HPCD/1% NaHCO30.25% DMSO/5% Dextrose/H2O5% Glucose/H2O |
| Actinomycin D | 7 | 0.06 mg/kg | i.v. | 5 days per week *(OFF after 2 weeks)* | Saline |
| Alisertib | 4 | 30 mg/kg | p.o. | 5 days per week | 10% HPCD/1% NaHCO3 |
| Decitabine | 5 | 2.5 mg/kg | i.p. | 1 day per week | Saline |
| Doxorubicin(Caelyx®) | 6 | 7 mg/kg | i.p. | 2 consecutive days every second week | 5% Glucose/H2O |
| MLN0128 | 8 | 3 mg/kg | p.o. | 3 days per week | 5% NMP/15% PVP |
| Panobinostat | 4 | 10 mg/kg | i.p. | 5 days per week | 0.25% DMSO/5% Dextrose/H2O |
| Topotecan | 8 | 2.5 mg/kg | i.p. | 5 days per week | Saline |
| Vincristine | 6 | 0.5 mg/kg | i.v. | 2 days per week | Saline |
| Volasertib | 8 | 25 mg/kg | i.v. | 2 consecutive days per week | NaCl/Saline |